| Q37809255 | Anesthesia for Patients on Buprenorphine |
| Q34615753 | Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy |
| Q34667890 | Buprenorphine: new treatment of opioid addiction in primary care. |
| Q35684589 | Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures |
| Q38979580 | Continuous Perioperative Sublingual Buprenorphine |
| Q33837599 | Depot naltrexone: long-lasting antagonism of the effects of heroin in humans |
| Q33429971 | Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology |
| Q35633106 | Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial |
| Q35023989 | Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial |
| Q36808909 | Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users |
| Q34126256 | Endogenous opiates: 1999. |
| Q64064745 | Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco |
| Q34101170 | Modification of perseverative responding that increased earnings but impeded skill acquisition in a job-skills training program. |
| Q37999447 | Naltrexone in the treatment of opioid-dependent pregnant women: the case for a considered and measured approach to research |
| Q44340798 | Opioid effects and opioid withdrawal during a 24 h dosing interval in patients maintained on buprenorphine |
| Q36227574 | Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment |
| Q44346900 | Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects |
| Q44341477 | Phase I study of injectable, depot naltrexone for the relapse prevention treatment of opioid dependence |
| Q37452336 | Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: rationale and design of the NAOMI study. |
| Q33837609 | Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers |
| Q42701015 | The Effects of Pharmacological Opioid Blockade on Neural Measures of Drug Cue-Reactivity in Humans |
| Q30490602 | The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data. |
| Q37089324 | Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. |
| Q26829140 | Update on the clinical use of buprenorphine: in opioid-related disorders |
| Q35558316 | Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist |
| Q26865674 | Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence |
| Q45847009 | Mise à jour sur l’utilisation clinique de la buprénorphine: pour les troubles reliés aux opioïdes |
Search more.